Compare Sun Pharma with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs AUROBINDO PHARMA - Comparison Results

SUN PHARMA     Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA AUROBINDO PHARMA SUN PHARMA/
AUROBINDO PHARMA
 
P/E (TTM) x 22.4 9.8 229.4% View Chart
P/BV x 2.6 1.8 145.5% View Chart
Dividend Yield % 0.6 0.6 104.3%  

Financials

 SUN PHARMA   AUROBINDO PHARMA
EQUITY SHARE DATA
    SUN PHARMA
Mar-19
AUROBINDO PHARMA
Mar-19
SUN PHARMA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs679830 81.8%   
Low Rs375527 71.2%   
Sales per share (Unadj.) Rs121.1333.9 36.3%  
Earnings per share (Unadj.) Rs13.440.4 33.1%  
Cash flow per share (Unadj.) Rs20.751.8 40.0%  
Dividends per share (Unadj.) Rs2.752.50 110.0%  
Dividend yield (eoy) %0.50.4 141.6%  
Book value per share (Unadj.) Rs172.6237.1 72.8%  
Shares outstanding (eoy) m2,399.26585.91 409.5%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.42.0 214.1%   
Avg P/E ratio x39.416.8 234.4%  
P/CF ratio (eoy) x25.513.1 194.4%  
Price / Book Value ratio x3.12.9 106.7%  
Dividend payout %20.66.2 331.9%   
Avg Mkt Cap Rs m1,264,650397,569 318.1%   
No. of employees `00017.517.9 98.0%   
Total wages/salary Rs m59,67125,849 230.8%   
Avg. sales/employee Rs Th16,608.110,956.9 151.6%   
Avg. wages/employee Rs Th3,409.61,447.7 235.5%   
Avg. net profit/employee Rs Th1,833.81,324.3 138.5%   
INCOME DATA
Net Sales Rs m290,659195,636 148.6%  
Other income Rs m10,2551,553 660.2%   
Total revenues Rs m300,914197,189 152.6%   
Gross profit Rs m63,07639,519 159.6%  
Depreciation Rs m17,5336,680 262.5%   
Interest Rs m5,5532,626 211.4%   
Profit before tax Rs m50,24631,767 158.2%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-12,144-881 1,379.0%   
Tax Rs m6,0097,269 82.7%   
Profit after tax Rs m32,09323,645 135.7%  
Gross profit margin %21.720.2 107.4%  
Effective tax rate %12.022.9 52.3%   
Net profit margin %11.012.1 91.4%  
BALANCE SHEET DATA
Current assets Rs m310,692153,645 202.2%   
Current liabilities Rs m173,396120,429 144.0%   
Net working cap to sales %47.217.0 278.2%  
Current ratio x1.81.3 140.4%  
Inventory Days Days99135 73.3%  
Debtors Days Days11264 175.2%  
Net fixed assets Rs m232,477103,909 223.7%   
Share capital Rs m2,399586 409.5%   
"Free" reserves Rs m411,691138,322 297.6%   
Net worth Rs m414,091138,908 298.1%   
Long term debt Rs m15,2261,800 846.1%   
Total assets Rs m646,938264,544 244.5%  
Interest coverage x10.013.1 76.7%   
Debt to equity ratio x00 283.8%  
Sales to assets ratio x0.40.7 60.8%   
Return on assets %5.89.9 58.6%  
Return on equity %7.817.0 45.5%  
Return on capital %10.223.8 42.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m66,02597,316 67.8%   
Fx outflow Rs m38,61040,589 95.1%   
Net fx Rs m27,41556,727 48.3%   
CASH FLOW
From Operations Rs m21,96516,220 135.4%  
From Investments Rs m-6,813-28,768 23.7%  
From Financial Activity Rs m-27,30519,191 -142.3%  
Net Cashflow Rs m-8,4426,656 -126.8%  

Share Holding

Indian Promoters % 63.7 54.1 117.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 8.0 64.5%  
FIIs % 23.0 27.7 83.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 10.2 81.4%  
Shareholders   133,026 69,601 191.1%  
Pledged promoter(s) holding % 0.5 8.6 6.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   VENUS REMEDIES  PROCTER & GAMBLE HEALTH  NOVARTIS  TTK HEALTHCARE  DR. REDDYS LAB  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Why is Sensex at a Record High When Economy is in Trouble?(Podcast)

In today's episode, I talk about all the major moves of the week, including Modi government's blockbuster disinvestment, developments in the telecom sector.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 38.6% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 38.6% YoY). Sales on the other hand came in at Rs 54 bn (up 28.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

I Think Nestle, HUL, and Asian Paints Could Give Low Returns(Profit Hunter)

Nov 15, 2019

If you think high quality stocks will continue their dream run forever, then you must read this now.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Nov 22, 2019 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS